AIMEDBIO

• - AimedBio’s FGFR3-targeting ADC candidate AMB302 has been designated as an Orphan Drug by the U.S. FDA for head and neck cancer.
• - Following its previous FDA IND clearance, AMB302 is being developed as a first-in-class ADC using a topoisomerase I (Topo1) payload.
  
  

Link: https://www.medicopharma.co.kr/news/articleView.php?idxno=63690